دورية أكاديمية
In Vitro Testing of Trichomonas vaginalis Drug Susceptibility: Evaluation of Minimal Lethal Concentrations for Metronidazole and Tinidazole That Correspond With Treatment Failure.
| العنوان: | In Vitro Testing of Trichomonas vaginalis Drug Susceptibility: Evaluation of Minimal Lethal Concentrations for Metronidazole and Tinidazole That Correspond With Treatment Failure. |
|---|---|
| المؤلفون: | Augostini P; From the Laboratory Science and Diagnostics Branch, Division of Parasitic Disease and Malaria, Centers for Disease Control and Prevention., Bradley ELP; Rollins School of Public Health, Emory University, Atlanta, GA., Raphael BH; From the Laboratory Science and Diagnostics Branch, Division of Parasitic Disease and Malaria, Centers for Disease Control and Prevention., Secor WE; From the Laboratory Science and Diagnostics Branch, Division of Parasitic Disease and Malaria, Centers for Disease Control and Prevention. |
| المصدر: | Sexually transmitted diseases [Sex Transm Dis] 2023 Jun 01; Vol. 50 (6), pp. 370-373. Date of Electronic Publication: 2023 Mar 24. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: J B Lippincott Country of Publication: United States NLM ID: 7705941 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-4521 (Electronic) Linking ISSN: 01485717 NLM ISO Abbreviation: Sex Transm Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Philadelphia Pa : J B Lippincott Original Publication: Philadelphia, Lippincott. |
| مواضيع طبية MeSH: | Trichomonas vaginalis* , Trichomonas Vaginitis*/drug therapy , Trichomonas Infections*/drug therapy, Female ; Humans ; Metronidazole/pharmacology ; Metronidazole/therapeutic use ; Tinidazole/therapeutic use ; Pharmaceutical Preparations ; Drug Resistance ; Treatment Failure ; In Vitro Techniques |
| مستخلص: | Background: The only drugs approved by the US Food and Drug Administration for oral treatment of trichomoniasis belong to the 5-nitroimidazole group. Most individuals infected with Trichomonas vaginalis can be cured with a standard treatment of metronidazole or tinidazole, but it is estimated that more than 159,000 people fail treatment each year. Although a minimal lethal concentration (MLC) corresponding to treatment failure has been reported for metronidazole, the MLC for tinidazole associated with treatment failure has not been determined. We conducted a study using T. vaginalis isolates from women with reported treatment success or failure to determine these values. Methods: We measured MLCs of 47 isolates obtained from women who had failed metronidazole treatment, 33 isolates from women who had failed tinidazole treatment, and 48 isolates from women successfully cured with metronidazole. The cutoff was calculated as the 95th percentile of MLCs of susceptible isolates for each drug. Results: Our data confirmed that the MLC previously associated with metronidazole treatment failure is ≥50 μg/mL and identified the MLC associated with tinidazole treatment failure as ≥6.3 μg/mL. For metronidazole, the agreement between laboratory result and treatment outcome was 93.7%; for tinidazole, this agreement was 88.9%. Conclusions: The T. vaginalis susceptibility assay is useful for determining whether 5-nitroimidazole treatment failure in persons with trichomoniasis can be attributed to drug resistance. These results are useful for establishing interpretive guidance of test results, and MLC levels can help guide appropriate patient treatment. Competing Interests: Conflict of Interest and Sources of Funding: All authors declare no conflicts of interest. This project was supported by the Centers for Disease Control and Prevention operating budget and involved no external funding. (Copyright © 2023 Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.) |
| References: | Kreisel KM, Spicknall IH, Gargano JW, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2018. Sex Transm Dis 2021; 48:208–214. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. Bull World Health Organ 2019; 97:548–562P. Kissinger PJ, Gaydos CA, Seña AC, et al. Diagnosis and management of Trichomonas vaginalis : Summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention sexually transmitted infections treatment guidelines. Clin Infect Dis 2022; 74(Suppl_2):S152–S161. Van Gerwen OT, Craig-Kuhn MC, Jones AT, et al. Trichomoniasis and adverse birth outcomes: A systematic review and meta-analysis. BJOG 2021; 128:1907–1915. Van Gerwen OT, Camino AF, Sharma J, et al. Epidemiology, natural history, diagnosis, and treatment of Trichomonas vaginalis in men. Clin Infect Dis 2021; 73:1119–1124. Patel EU, Gaydos CA, Packman ZR, et al. Prevalence and correlates of Trichomonas vaginalis infection among men and women in the United States. Clin Infect Dis 2018; 67:211–217. Masha SC, Cools P, Sanders EJ, et al. Trichomonas vaginalis and HIV infection acquisition: A systematic review and meta-analysis. Sex Transm Infect 2019; 95:36–42. Muzny CA, Van Gerwen OT. Secnidazole for trichomoniasis in women and men. Sex Med Rev 2022; 10:255–262. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006; 50:4209–4210. Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD surveillance network, 2009–2010. Emerg Infect Dis 2012; 18:939–943. Secor WE, Meites E, Starr MC, et al. Neglected parasitic infections in the United States: Trichomoniasis. Am J Trop Med Hyg 2014; 90:800–804. Bosserman EA, Helms DJ, Mosure DJ, et al. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis infected women with clinical treatment failure. Sex Transm Dis 2011; 38:983–987. Müller M, Lossick JG, Gorrell TE. In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Transm Dis 1988; 15:17–24. DiClemente RJ, Rosenbaum JE, Rose ES, et al. Horizons and group motivational enhancement therapy: HIV prevention for alcohol-using young black women, a randomized experiment. Am J Prev Med 2021; 60:629–638. Diamond LS. The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol 1957; 43:488–490. Meingassner JG, Thurner J. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother 1979; 15:254–257. Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis . Antimicrob Agents Chemother 1996; 40:1121–1125. Lockhart SR, Ghannoum MA, Alexander BD. Establishment and use of epidemiological cutoff values for molds and yeasts by use of the Clinical and Laboratory Standards Institute M57 standard. J Clin Microbiol 2017; 55:1262–1268. Paulish-Miller TE, Augostini P, Schuyler JA, et al. Trichomonas vaginalis metronidazole resistance is associated with single nucleotide polymorphisms in the nitroreductase genes ntr4Tv and ntr6Tv. Antimicrob Agents Chemother 2014; 58:2938–2943. Lazenby GB, Thompson L, Powell AM, et al. Unexpected high rates of persistent Trichomonas vaginalis infection in a retrospective cohort of treated pregnant women. Sex Transm Dis 2019; 46:2–8. Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis . Antimicrob Agents Chemother 2003; 47:1407–1409. Crowell AL, Stephens CE, Kumar A, et al. Evaluation of dicationic compounds for activity against Trichomonas vaginalis . Antimicrob Agents Chemother 2004; 48:3602–3605. Goodhew EB, Secor WE. Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates. Sex Transm Infect 2013; 89:479–484. Graves KJ, Novak J, Secor WE, et al. A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis . Parasitology 2020; 147:1383–1391. |
| معلومات مُعتمدة: | CC999999 United States ImCDC Intramural CDC HHS |
| المشرفين على المادة: | 140QMO216E (Metronidazole) 033KF7V46H (Tinidazole) Y8U32AZ5O7 (4-nitroimidazole) 0 (Pharmaceutical Preparations) |
| تواريخ الأحداث: | Date Created: 20230227 Date Completed: 20230515 Latest Revision: 20230823 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10175203 |
| DOI: | 10.1097/OLQ.0000000000001788 |
| PMID: | 36849257 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-4521 |
|---|---|
| DOI: | 10.1097/OLQ.0000000000001788 |